Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
Mid-Afternoon Market Update: Vera Bradley Surges On Narrower-Than-Expected Loss; EnerSys Shares Slide
Benzinga's Option Alert Recap From April 11
Related BMY
These Were The Most Popular Buys And Sells Among Retail Investors In June
TD Ameritrade's Investor Movement Index (IMX) For June 2017
Conestoga Capital Advisors, LLC Buys ESCO Technologies Inc, Vocera Communications Inc, The ... (GuruFocus)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

View Comments and Join the Discussion!